24
19
1
49
2
2
2c
1b
1d
18
31
8c
1d
2 29
1d
25
Mark H. O'Hara, MD
78
8c
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
3
2
4
b
1f
4d
Division of Hematology Oncology
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-306
39 3400 Civic Center Blvd
Philadelphia, PA 19104
26
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-306
39 3400 Civic Center Blvd
Philadelphia, PA 19104
2f
Office: (215)360-0735
33 Fax: (215)662-4646
24
a3
12
33 Fax: (215)662-4646
24
13
Education:
21 7 BS 29 (Biology - Molecular Genetics) c
30 University of Rochester, 2004.
21 7 MD 15 (Medicine) c
37 Stony Brook School of Medicine, 2008.
c
3
3
3
3
8d
Permanent link21 7 BS 29 (Biology - Molecular Genetics) c
30 University of Rochester, 2004.
21 7 MD 15 (Medicine) c
37 Stony Brook School of Medicine, 2008.
c
2 29
21
1e
1d
24
5e
71
e 29
27
Description of Clinical Expertise
c4 GI Cancers, Phase 1 Trials, Pancreatic Cancer, Colorectal Cancer, Anal Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Neuroendocrine Tumor71
Description of Research Expertise
5d Pancreatic Cancer, Colorectal Cancer, GI Cancers, Phase 1, CAR T Cell Therapye 29
23
23c Khalil DN, Gomez R, Regev A, Samaan F, Marouf Y, Budhu S, Hirschhorn D, Schulze I, Lavery JA, Ceglia N, Freeman SS, Maltez VI, Garcia JM, Suek N, Weng CH, Cabanski CR, Monette S, Romin Y, Li Y, Chaligne R, Yellin MJ, Keler T, Maurer DM, Flamar AL, Morgado-Palacin L, Mangarin LM, Harding JJ, Park W, Lyman JP, Maddock S, O'Hara MH, Abou-Alfa GK, Vonderheide RH, O'Reilly EM, Germain RN, Wolchok JD, Merghoub T.: IL-10R inhibition induces neutrophil tumoricidal activity. Cancer Immunol Res Jan 2026.
20e Till JE, Gal-Rosenberg O, Giliberto SG, Seewald NJ, Ballinger DG, Samberg HE, Yin MR, Wang QL, Cannas S, Kim KN, Tien K, Sawi M, Madineedi V, Furniss CS, Gocheva V, Nowak J, Brais LK, Yuan C, Rosenthal MH, Roses R, DeMatteo R, Lee MK, Vollmer C, Sagreiya H, O'Hara MH, Shemer R, Wolpin B, Dor Y, Carpenter EL.: Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Clin Transl Med Jan 2026.
240 O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH.: Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. J Immunother Cancer 14: e012864, Jan 2026.
22a Barber-Rotenberg JS, Haas AR, Aggarwal C, O'Hara M, Hexner E, Pequignot E, Dowd E, Ndeupen S, Thai E, Chen F, Oner BS, Czuczman C, Gonzalez VE, Fraietta JA, Hwang WT, Chew A, Jadlowsky JK, Marshall A, Shea KM, Jiang Y, Cosey A, Ferthio R, Levine BL, Plesa G, Siegel DL, Young RM, Sheppard NC, Albelda SM, June CH, Tanyi JL.: Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. Mol Ther Jan 2026.
213 Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH.: Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell Rep Med Aug 2025.
1b8 Amit U, Metz JM, Plastaras JP, Gheewala R, Teitelbaum U, Damjanov N, Vollmer C, Schneider CJ, Lee MK 4th, O'Hara M, Reiss-Binder K, Carpenter EL, Karasic TB, Konski A, Wileyto EP, Ben-Josef E.: A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Cancer 131: e35936, Jun 2025.
fa Swami N, Hwang WT, Mamtani R, O'Hara MH, Chapin WJ.: Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer. JAMA Netw Open 8: e2515087, Jun 2025.
23a Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O'Hara MH, Eads J, King D, Shah MA, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA.: Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group. JCO Precis Oncol Mar 2025.
ff Than MT, O'Hara M, Stanger BZ, Reiss KA.: KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma. Molecular Cancer Therapeutics 23(10): 1378 - 1388, Oct 2024.
2c
7
1d
1f
Selected Publications
1cf Reiss KA, Xia M, Akamandisa M, D'Andrea K, Wubbenhorst B, Lord CJ, Pettitt SJ, Tutt ANJ, Brown TJ, O'Hara MH, Schneider C, Teitelbaum U, Hannan Z, Hood R, Tondon R, Vonderheide RH, Domchek SM, Nathanson KL.: Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial. JAMA Oncol Apr 2026.23c Khalil DN, Gomez R, Regev A, Samaan F, Marouf Y, Budhu S, Hirschhorn D, Schulze I, Lavery JA, Ceglia N, Freeman SS, Maltez VI, Garcia JM, Suek N, Weng CH, Cabanski CR, Monette S, Romin Y, Li Y, Chaligne R, Yellin MJ, Keler T, Maurer DM, Flamar AL, Morgado-Palacin L, Mangarin LM, Harding JJ, Park W, Lyman JP, Maddock S, O'Hara MH, Abou-Alfa GK, Vonderheide RH, O'Reilly EM, Germain RN, Wolchok JD, Merghoub T.: IL-10R inhibition induces neutrophil tumoricidal activity. Cancer Immunol Res Jan 2026.
20e Till JE, Gal-Rosenberg O, Giliberto SG, Seewald NJ, Ballinger DG, Samberg HE, Yin MR, Wang QL, Cannas S, Kim KN, Tien K, Sawi M, Madineedi V, Furniss CS, Gocheva V, Nowak J, Brais LK, Yuan C, Rosenthal MH, Roses R, DeMatteo R, Lee MK, Vollmer C, Sagreiya H, O'Hara MH, Shemer R, Wolpin B, Dor Y, Carpenter EL.: Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Clin Transl Med Jan 2026.
240 O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH.: Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. J Immunother Cancer 14: e012864, Jan 2026.
22a Barber-Rotenberg JS, Haas AR, Aggarwal C, O'Hara M, Hexner E, Pequignot E, Dowd E, Ndeupen S, Thai E, Chen F, Oner BS, Czuczman C, Gonzalez VE, Fraietta JA, Hwang WT, Chew A, Jadlowsky JK, Marshall A, Shea KM, Jiang Y, Cosey A, Ferthio R, Levine BL, Plesa G, Siegel DL, Young RM, Sheppard NC, Albelda SM, June CH, Tanyi JL.: Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers. Mol Ther Jan 2026.
213 Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH.: Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell Rep Med Aug 2025.
1b8 Amit U, Metz JM, Plastaras JP, Gheewala R, Teitelbaum U, Damjanov N, Vollmer C, Schneider CJ, Lee MK 4th, O'Hara M, Reiss-Binder K, Carpenter EL, Karasic TB, Konski A, Wileyto EP, Ben-Josef E.: A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Cancer 131: e35936, Jun 2025.
fa Swami N, Hwang WT, Mamtani R, O'Hara MH, Chapin WJ.: Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer. JAMA Netw Open 8: e2515087, Jun 2025.
23a Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O'Hara MH, Eads J, King D, Shah MA, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA.: Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group. JCO Precis Oncol Mar 2025.
ff Than MT, O'Hara M, Stanger BZ, Reiss KA.: KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma. Molecular Cancer Therapeutics 23(10): 1378 - 1388, Oct 2024.
2c
44
23
Back to Top
1b
1d
18